Disarming Pancreatic Cancer With Enzyme Inhibitors
-
- 1
Researchers at West Virginia University are advancing pancreatic cancer treatment by targeting a specific enzyme, myeloperoxidase, which typically aids in fighting infections but exacerbates cancer when overactive. The study, inspired by poor outcomes in existing therapies and a survival rate of only 13% for pancreatic cancer patients, explores how inhibiting this enzyme could enhance the […]
Source link
Researchers at West Virginia University are advancing pancreatic cancer treatment by targeting a specific enzyme, myeloperoxidase, which typically aids in fighting infections but exacerbates cancer when overactive. The study, inspired by poor outcomes in existing therapies and a survival rate of only 13% for pancreatic cancer patients, explores how inhibiting this enzyme could enhance the…
Researchers at West Virginia University are advancing pancreatic cancer treatment by targeting a specific enzyme, myeloperoxidase, which typically aids in fighting infections but exacerbates cancer when overactive. The study, inspired by poor outcomes in existing therapies and a survival rate of only 13% for pancreatic cancer patients, explores how inhibiting this enzyme could enhance the…